Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP13 | P45452 | 9/20 | 0.52 |
| ▸ | ROCK2 | O75116 | 6/20 | 0.45 |
| ▸ | ROCK1 | Q13464 | 5/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.43 |
| ▸ | CASP3 | P42574 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.43 |
| ▸ | RELA | Q04206 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.43 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.43 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.43 |
| ▸ | PSMB2 | P49721 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6699569 | 0.85 | MMP13 (0.57) | MMP13ROCK2ROCK1SMN1; SMN2KDM4E | |
| SCHEMBL6298027 | 0.79 | MMP13 (0.81) | MMP13 | |
| SCHEMBL6698254 | 0.76 | MEN1 (0.52) | MMP13ROCK2ROCK1ALDH1A1SMN1; SMN2 | |
| SCHEMBL6699913 | 0.75 | MMP13 (0.69) | MMP13ROCK2ROCK1KDM4EMEN1 | |
| SCHEMBL6698566 | 0.74 | MMP13 (0.47) | MMP13 | |
| SCHEMBL6681942 | 0.73 | MMP13 (0.46) | MMP13ALDH1A1SMN1; SMN2PKM | |
| SCHEMBL6704886 | 0.71 | MMP13 (0.56) | MMP13ALDH1A1SMN1; SMN2KDM4EMEN1 | |
| SCHEMBL6822798 | 0.71 | MMP13 (0.56) | MMP13ALDH1A1SMN1; SMN2KDM4EMEN1 | |
| SCHEMBL6168071 | 0.70 | MMP13 (0.54) | MMP13 | |
| SCHEMBL5696853 | 0.70 | MMP13 (0.73) | MMP13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040038994-A1 | Pyrimidine fused bicyclic metalloproteinase inhibitors | WILSON MICHAEL WILLIAM (US) | 2004-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040038994-A1 | Pyrimidine fused bicyclic metalloproteinase inhibitors | MMP9, MMP1, MMP2 | MMP13 13/4885ROCK2 2357/4885ROCK1 1018/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.